← Back to Search

Single dose of DZD8586 for Non-Hodgkin's Lymphoma

Phase 1
Waitlist Available
Led By Frank Lee
Research Sponsored by Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is testing a new drug in healthy adults. It will help identify possible side effects and measure how the drug behaves in the body.

Eligible Conditions
  • Non-Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Single dose of DZD8586Experimental Treatment1 Intervention
Single dose of DZD8586
Group II: Single dose of PlaceboPlacebo Group1 Intervention
Single dose of Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DZD8586
2021
Completed Phase 1
~70

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Dizal (Jiangsu) Pharmaceutical Co., Ltd.Lead Sponsor
2 Previous Clinical Trials
200 Total Patients Enrolled
Frank LeePrincipal InvestigatorFrontage Clinical Services, Inc.
1 Previous Clinical Trials
15 Total Patients Enrolled
~17 spots leftby Nov 2025